Chairman of Tasly Bio-medicine Industry Group Co., Ltd; Dr. Kaijing Yan leads the strategic development of the Tasly Institute of Life Rejuvenation, which he founded to advance the clinical translation of next-generation regenerative therapies. Under his vision, the institute was established as an interdisciplinary platform integrating AI, single-cell omics, and regenerative medicine to redefine the identity and function of mesenchymal stromal cells. His pioneering work includes the development of an AI-based system for MSC safety prediction and personalization, and the creation of the world’s first FDA-recognized clinical standard for MSCs—laying a global foundation for regulatory and therapeutic innovation in the field.

Former Executive Director, Tennessee Institute of  Immunology Laboratory; Former Professor and Director,  Hubei University of Medicine. His translational research focuses on clinical-grade stem cell technology, including scalable production, cryopreservation, and quality control of adipose-derived stem cells (ADSCs). His work supports the development of ADSC-based therapies for intractable diseases and advances stem cell biomanufacturing through automation platforms and derivative product innovation, including bioactive cosmetics.

Ph.D. in Stem Cell Research, University of Edinburgh; Postdoctoral Fellow, MRC Centre for Regenerative Medicine, UK. He led the development of the world’s first allogeneic mesenchymal stromal cell (MSC) sheet for the treatment of ischemic cardiomyopathy, as well as the first adipose derived MSC product for ischemic stroke. 

Ph.D. in Cell Biology, West China Hospital, Sichuan University. He focuses on understanding MSCs' mechanisms of action in vivo. He provides critical biological insights that support their clinical application.

Ph.D. in Biochemical Engineering, Tianjin University. He specializes in cell biology, metabolic engineering, and synthetic biology, which research listed among China's "Top 10 Scientific Advances" (2017). Establishes single-cell omics analysis platform, supported the world’s first mesenchymal stromal cell identification method.

M.S. in Biochemistry and Molecular Biology, Ocean University of China. Certified IBM AI Professional Engineer and Google TensorFlow Developer, and an expert in bioinformatics. He has developed multiple AI- and big data-based tools and methods for mesenchymal stromal cell (MSC) research, including the world's first identification method and standard for MSCs. 

Ph.D. in Biomedical Science, University of Tennessee. She focuses on 3D bioprinting and microenvironment simulation. She developed the first Biosynsphere system for vascular tissue fabrication using stem cells.

M.D.-Ph.D. and Postdoc, West China Hospital, Sichuan University. He specializes in cardiovascular regeneration and regulatory strategy. He has led preclinical development and FDA/CDE submissions for cell therapies, and built partnerships with global firms.

Ph.D. in Chemistry & M.S. in Computer Science, Stanford University. He develops AI models to support precision cell therapy design. His work models how microenvironments influence MSC function and therapeutic outcomes.

M.S. in Botany, Shenyang Agricultural University. She focuses on CMC development and quality control for MSCs. She led the process development for the world's first adipose-derived MSC stroke therapy approved by both the FDA and CDE.

MBA, Nankai University. With over a decade of experience in the pharmaceutical industry, she contributed to the founding of TILR and has proven strengths in management and project operations. She is currently focused on building strategic partnerships to accelerate business development and deliver long-term value.

M.S. in Biomedical Engineering, Southeast University, China; M.S. in Nanotechnology, Ulm University, Germany. She specializes in portfolio development and application filing for cell therapy and AI projects. The patents she represented in prosecution have been awarded the China Patent Award.

M.Sc. in Global Health, University of Southampton, UK. He specializes in health information technology (HIT) and the application of artificial intelligence in healthcare. He has led the development of multiple medical devices and has participated in the deployment of large-scale regional health information systems, focusing on integrating AI to enhance healthcare delivery and operational efficiency.

M.S. in Food Science and Engineering，Tianjin University of China. She is dedicated to the quality research of mesenchymal stromal cells and participated in the formulation of the world's first identification standard for mesenchymal stromal cells distinct from stem cells.

M.S. in Biochemistry and Molecular Biology, Nankai University, China. With over a decade of dedicated experience in the single-cell sequencing analysis industry, She participated in the formulation of the world's first identification standard for mesenchymal stromal cells(MSCs) distinct from stem cells and the quality assessment method research of MSCs by the single-cell sequencing.

M.S. in Landscape Plants and Ornamental Horticulture, Huazhong Agricultural University, China. She brings over eight years of specialized experience in single-cell sequencing analysis. She contributed to the development of the world's first identification standard differentiating mesenchymal stromal cells (MSCs) from stem cells, supporting regulatory clarity and product classification in the field of regenerative medicine. 

M.S. in Pharmaceutical Sciences, Chongqing University of Technology. Mr. Wang leads research on real-time, in vivo tracking of mesenchymal stromal cells (MSCs) using advanced two-photon excitation microscopy. His work has established novel methodologies for quantifying MSC function in living systems, contributing to deeper insights into cellular behavior and advancing the evaluation of regenerative therapies.

M.S. in Biochemical Engineering, Tianjin University. She has over a decade of experience in product development and has led the successful launch of multiple clinical molecular diagnostic products. She brings specialized expertise in culture medium formulation and optimization, with a strong focus on regulatory mechanisms of the MSC microenvironment. 

M.M. in Medical Biomedical Engineering,Norman Bethune College of Medicine, Jilin University.She specializes in the technological promotion of MSCs and the translational application of cell therapy products.

M.M. in Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine. She focuses on developing in vivo functional validation platforms for mesenchymal stromal cells (MSCs), supporting the evaluation of their therapeutic efficacy and biological activity in regenerative applications.

M.S. in Genetics, Hebei Normal University. He specializes in the functional characterization of mesenchymal stromal cells (MSCs) using single-cell sequencing technologies. He is also engaged in the development of microfluidics-based rapid detection platforms to support high-throughput analysis and quality assessment of MSCs.

M.S. in Animal Science, Northeast Forestry University. He specializes in functional analysis of mesenchymal stromal cells (MSCs) using single-cell sequencing technologies. He is also involved in the development of rapid assay chips for MSC identity verification, supporting standardized evaluation of cell function.